Coverage by the news media of the benefits and risks of medications

New England Journal of Medicine

Volumn 342, Issue 22, 2000, Pages 1645-1650

  Moynihan, Ray ^a   Bero, Lisa ^b,c   Ross Degnan, Dennis ^f   Henry, David ^a,d   Lee, Kirby ^b   Watkins, Judy ^f   Mah, Connie ^f   Soumerai, Stephen B ^d,e  

^a Australian Broadcasting Corp   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; PRAVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MONITORING; FEMALE; FINANCIAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE DIAGNOSIS; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; TELEVISION;

BIOMEDICAL AND BEHAVIORAL RESEARCH; BIOMEDICAL RESEARCH; CLINICAL APPROACH/SOURCE; COSTS AND BENEFITS; EMPIRICAL APPROACH; PROFESSIONAL PATIENT RELATIONSHIP; RISKS AND BENEFITS; UNITED STATES;

ALENDRONATE; ANTICHOLESTEREMIC AGENTS; ASPIRIN; BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CONFLICT OF INTEREST; COST-BENEFIT ANALYSIS; DISCLOSURE; DRUG THERAPY; FEES, PHARMACEUTICAL; HUMANS; JOURNALISM, MEDICAL; MASS MEDIA; NEWSPAPERS; OSTEOPOROSIS; PRAVASTATIN; RISK ASSESSMENT; TELEVISION; UNITED STATES;

EID: 0034213577     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200006013422206     Document Type: Article

References (43)

1. Americans talk about science and medical news: the National Health Council Report. New York: Roper Starch Worldwide, 1997.
2. Oxman AD, Guyatt GH, Cook DJ, Jaeschke R, Heddle N, Keller J. An index of scientific quality for health reports in the lay press. J Clin Epidemiol 1993;46:987-1001.
3. Angell M, Kassirer JP. Clinical research - what should the public believe? N Engl J Med 1994;331:189-90.
4. Sitthi-amorn C, Ngamvithayapongse J. The role of media and communication in improving the use of drugs and other technologies. Int J Technol Assess Health Care 1998;14:71-80.
5. Dan B. TV or not TV: communicating health information to the public. JAMA 1992;268:1026-7.
6. Entwistle V. Reporting research in medical journals and newspapers. BMJ 1995;310:920-3.
7. Kennedy GE, Bero LA. Print media coverage of research on passive smoking. Tob Control 1999;8:254-60.
8. Grilli R, Freemantle N, Minozzi S, Domenighetti G, Finer D. Mass media interventions: effects on health services utilisation. York, England: Cochrane Collaboration, 2000. (See: http://www.ebando.com/band16/ b16-7.html.)
9. Van Trigt A, de Jong-van den Berg LT, Haaijer-Ruskamp FM, Willems J, Tromp TF. Journalists and their sources of ideas and information on medicines. Soc Sci Med 1994;38:637-43.
10. Nelkin D. An uneasy relationship: the tensions between medicine and the media. Lancet 1996;347:1600-3.
11. Schwartz LM, Woloshin S, Welch HG. Misunderstandings about the effects of race and sex on physicians' referrals for cardiac catheterization. N Engl J Med 1999;341:279-83.
12. Loo LK, Byrne JM, Hardin SB, Castro D, Fisher FP. Reporting medical information: does the lay press get it right? J Gen Intern Med 1998; 13:Suppl 1:60. abstract.
13. Brown I, Chapman S, Lupton D. Infinitesimal risk as public health crisis: news media coverage of a doctor-patient HIV contact tracing investigation. Soc Sci Med 1996;43:1685-95.
14. Lebow M. The pill and the press: reporting risk. Obstet Gynecol 1999;93:453-6.
15. Remuzzi G, Schieppati A. Lessons from the Di Bella affair. Lancet 1999;353:1289-90.
16. Myers M. "Drug may have caused huge number of deaths": lessons learned during an encounter with the Fifth Estate. CMAJ 1996;155:772-5.
17. Soumerai S, Ross-Degnan D, Kahn JS. Effects of professional and media warnings about the association between aspirin use in children and Reye's syndrome. Milbank Q 1992;70:155-82.
18. Hux J, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making 1995;15:152-7.
19. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
20. Bucher H, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4.
21. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet 1994;343: 1209-11.
22. Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ 1995;311: 1056-60.
23. JAMA instructions for authors. JAMA 1999;281:12-20.
24. Van Trigt A, de Jong-van den Berg LT, Voogt LM, Willems J, Tromp TF, Haaijer-Ruskamp FM. Setting the agenda: does the medical literature set the agenda for articles about medicines in the newspapers? Soc Sci Med 1995;41:893-9.
25. Shuchman M, Wilkes M. Medical scientists and health news reporting: a case of miscommunication. Ann Intern Med 1997;126:976-82.
26. Cho M, Bero L. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-9.
27. Davidson R. Source of funding and outcome of clinical trials. J Gen Intern Med 1986;1:155-8.
28. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
29. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
30. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312: 1563-6.
31. HMG-CoA reductase inhibitors: systemic. In: USP dispensing information. Vol. 1. Drug information for the health care professional. Englewood, Colo.: Micromedex, 1999:1647-51.
32. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
33. Donner A, Wells G. A comparison of confidence interval methods for the intraclass correlation coefficient. Biometrics 1986;42:401-12. [Erratum, Biometrics 1986;42:1009.]
34. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
35. Report on alendronate. ABC World News Tonight. May 22, 1996 (transcript).
36. Report on alendronate. NBC Nightly News. May 22, 1996 (transcript).
37. Report on alendronate. CBS Evening News. May 22, 1996 (transcript).
38. McCormack JP, Levine M. Meaningful interpretation of risk reduction from clinical drug trials. Ann Pharmacother 1993;27:1272-7.
39. Krimsky S, Rothenberg LS. Financial interest and its disclosure in scientific publications. JAMA 1998;280:225-6.
40. Melzer D. New drug treatment for Alzheimer's disease: lessons for healthcare policy. BMJ 1998;316:762-4.
41. Hazard seen in blood pressure drugs. Los Angeles Times. March 11, 1995:4.
42. Blood pressure drugs defended. The San Diego Tribune. March 15, 1995:A13.
43. Guyatt GH, Ray J, Gibson N, et al. A journalist's guide to writing health stories. Am Med Writers Assoc J 1999;14:32-41.